【Good News】Haibu Pharmaceutical's pregabalin oral solution has obtained a production license.

Indications

This product is used for the treatment ofpostherpetic neuralgia;fibromyalgia;as an adjunctive treatment for partial seizures in adults.

Product Advantages

Significant clinical efficacy:Pregabalin has been approved globally for multiple indications, including postherpetic neuralgia, fibromyalgia, neuropathic pain due to spinal cord injury, diabetic peripheral neuropathy, and as an adjunct therapy for partial seizures lasting one month or more. Both domestic and international guidelines consistently recommend Pregabalin as the first-line preferred medication for treating postherpetic neuralgia (PHN) and fibromyalgia (FM).

Good market prospects:Ruianxi^(®)is a strawberry-flavored oral solution that is convenient for children and patients with swallowing difficulties, which helps improve patient compliance; our company’s product is equipped with a precise dosing device, making it easier to adjust dosages for special populations and ensuring high medication adherence. It is a multi-indication drug with broad usage, classified as a Category B product under medical insurance, with high demand and good market prospects.

Mechanism of Action

Pregabalin is an analogue of the neurotransmitter gamma-aminobutyric acid (GABA). It reduces depolarization at nerve terminals and calcium ion influx by binding to and inhibiting the α2-δ subunit protein of voltage-gated calcium channels, thereby inhibiting the release of excitatory neurotransmitters such as L-glutamate (associated with seizures, pain, and anxiety).